Prognostic factors in patients with carcinoma of the uterine cervix treated with external beam irradiation and IR-192 high-dose-rate brachytherapy

Kapp, Karin S.; Stuecklschweiger, Georg; Kapp, Daniel S.; Poschauko, J.; Pickel, H.; Lahousen, M.; Hackl, A.

doi:10.1016/s0360-3016(98)00255-7

Cited by 76 publications

(46 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[22][23][24][25][26] In some HDR series, the overall treatment time was Ͼ 8 weeks, because 4 -5 fractions of HDR-ICBT were performed only after delivering 40 -45 Gy of EBRT. 5,8 In contrast, most of the patients in the current study were treated for a period within 6 weeks. The first ICBT was initiated as soon as possible to avoid the negative impact of treatment prolongation.…”

Section: Discussionmentioning

confidence: 91%

“…The strong correlation between tumor size and treatment outcome is well documented. 5,[22][23][24][25][26] The variation of treatment results among the different reports may be due to the wide range of tumor sizes, even for patients with the same stage of disease. The number of bulky tumors in our patient population was relatively small compared with the number of tumors in the American and European series, 22,23 and this might account for the more favorable outcome.…”

Section: Discussionmentioning

confidence: 99%

“…To achieve equivalent disease control to that achieved with LDR treatment without increasing the risk of late complications, various dosages and fractionation schedules of HDR-ICBT have been examined. Several studies, including nonrandomized [3][4][5][6][7][8][9] and randomized 10 -12 clinical trials, have demonstrated that HDR-ICBT was comparable to LDR-ICBT in terms of local control, survival, and morbidity rates. However, various fractionation schedules exist, and the optimum dose and fractionation schedule of ICBT and the appropriate combination of EBRT and ICBT remain controversial issues.…”

mentioning

confidence: 99%

“…However, to our knowledge there have been only a very few studies published to date in which disease status and late complications were monitored for Ͼ 10 years after treatment, although HDR-ICBT has been used extensively in Asia and Europe for Ͼ 3 decades. [3][4][5][7][8][9][10][11][12] Therefore, the safety of HDR treatment has not been investigated thoroughly.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Long‐term results of high‐dose rate intracavitary brachytherapy for squamous cell carcinoma of the uterine cervix

Nakano

Kato

Ohno³

et al. 2004

Cancer

146

100

View full text Add to dashboard Cite

BACKGROUNDThe authors performed a long‐term follow‐up study to evaluate the efficacy and late toxicity of high‐dose rate intracavitary brachytherapy (HDR‐ICBT) for cervical carcinoma.METHODSFrom 1968 to 1986, 1148 patients with Stage IB to IVB squamous cell carcinoma of the cervix (staging was performed according to the International Federation of Gynecology and Obstetrics) were treated with a combination of external beam radiotherapy (EBRT) and HDR‐ICBT. For patients with early‐stage disease, 20 gray (Gy) of EBRT was delivered to the whole pelvis, followed by 24 Gy/4 fractions of HDR‐ICBT and 30 Gy of central‐shielding EBRT. For patients with advanced‐stage disease, 20–40 Gy of whole pelvic EBRT was administered, followed by 24 Gy/4 fractions of ICBT and 30–10 Gy of central‐shielding EBRT. The overall treatment time was approximately 6 weeks. Among survivors, the follow‐up rate was 98% and the median follow‐up duration was 22 years.RESULTSThe 10‐year pelvic tumor control rates were 93% for patients with Stage IB disease, 82% for patients with Stage II disease, and 75% for patients with Stage III disease. The 10‐year overall and cause‐specific survival rates were 74% and 89% for patients with Stage IB disease, 52% and 74% for patients with Stage II disease, and 42% and 59% for patients with Stage III disease, respectively. The 10‐year actuarial rates of major complications were 4.4% in the rectosigmoid colon, 0.9% in the bladder, and 3.3% in the small intestines.CONCLUSIONSThe results of the current study suggest that the combination of EBRT and HDR‐ICBT according to the authors' protocol provided outcomes that were comparable to those of the conventional low‐dose rate brachytherapy with acceptable rates of late complications in the treatment of cervical carcinoma. Cancer 2005. © 2004 American Cancer Society.

show abstract

Section: Discussionmentioning

confidence: 91%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Long‐term results of high‐dose rate intracavitary brachytherapy for squamous cell carcinoma of the uterine cervix

Nakano

Kato

Ohno³

et al. 2004

Cancer

146

100

View full text Add to dashboard Cite

show abstract

“…Thus, the 5-year survival rate increased from 25% in 1973 to 47% in 1983 for Stage III cervix cancer (58). In particular, the bulky tumours with diameters above 6 cm remain a challenge (59,60). Even a radiation dose of 85 Gy resulted in 35 -50% pelvic failures in Stage IIB -III of cervix tumours (61).…”

Section: Hyperthermia In Deep-seated Tumoursmentioning

confidence: 99%

Status of Clinical Hyperthermia

Dahl

Dalene²,

Bc³

et al. 1999

Acta Oncologica

View full text Add to dashboard Cite

Uterine Cervix Cancer

Pitson

Fyles

2014

TNM Online

View full text Add to dashboard Cite

Carcinoma of the cervix accounts for approximately 20% of all gynecologic cancers and 2% of all malignancies in women. Numerous prognostic factors have been studied in patients with cervical carcinoma, using both univariate and multivariate analysis. Differences in endpoints of analysis, whether survival (disease‐free or overall), relapse‐free rate, or local control rate, make comparison of such studies difficult. The failure to perform a multivariate analysis, or the use of different covariates in multivariate analyses, can further complicate comparisons between studies. Not all factors are relevant to all patients; for example, depth of tumor invasion and presence of vascular‐space invasion can only be reliably determined in patients treated with surgery, whereas hemoglobin level is important in patients treated with radiation. This review concentrates largely on those factors identified using multivariate techniques, such as log rank or Cox regression analysis, in order to account for interactions between various factors. Where available, estimates such as hazard ratios will be included in order to indicate the strengths of the individual variables.

show abstract

Prognostic factors in patients with carcinoma of the uterine cervix treated with external beam irradiation and IR-192 high-dose-rate brachytherapy

Cited by 76 publications

References 62 publications

Long‐term results of high‐dose rate intracavitary brachytherapy for squamous cell carcinoma of the uterine cervix

Long‐term results of high‐dose rate intracavitary brachytherapy for squamous cell carcinoma of the uterine cervix

Status of Clinical Hyperthermia

Uterine Cervix Cancer

Contact Info

Product

Resources

About